[Osteoporotic fracture in menopausal women: alendronate reduces the risk]

Rev Med Suisse. 2008 Dec 10;4(183):2703.

[Article in French]

Authors

R Bize¹, O Lamy, I Peytremann-Bridevaux

Affiliation

¹ Institut universitaire de médecine sociale et préventive de l'Université de Lausanne et Réseau francophone Cochrane Bugnon 17, 1005 Lausanne.

PMID: 19157286

No abstract available

MeSH terms

Alendronate / administration & dosage
Alendronate / adverse effects
Alendronate / therapeutic use*
Bone Density Conservation Agents / administration & dosage
Bone Density Conservation Agents / adverse effects
Bone Density Conservation Agents / therapeutic use*
Female
Fractures, Bone / prevention & control*
Hip Fractures / prevention & control
Humans
Middle Aged
Osteoporosis, Postmenopausal / complications
Osteoporosis, Postmenopausal / drug therapy*
Primary Prevention
Risk Factors
Secondary Prevention
Spinal Fractures / prevention & control

Substances

Bone Density Conservation Agents
Alendronate